Skip to main content

Table 4 Validation of Calculated Hasford and Sokal Scores

From: Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study

  3-mo CHR, all treatments (n = 35) 3-mo CHR, imatinib only (n = 32)
  Yes No P Value Yes No P Value
Hasford Score    0.035    0.0454
   </=780 low-risk 17 (85%) 3 (15%)   16 (88.9%) 2 (11.1%)  
   >780 and </=1480 intermediate 5 (41.7%) 7 (58.3%)   5 (45.5%) 6 (55.5%)  
   >1480 high-risk 2 (66.7%) 1 (33.3%)   2 (66.7%) 1 (33.3%)  
Sokal Score    0.015    0.0043
   <0.8 good prognosis 14 (93.3%) 1 (6.7%)   13 (100%) 0 (0%)  
   0.8–1.2 moderate prognosis 7 (58.3%) 5 (41.7%)   7 (58.3%) 5 (41.7%)  
   >1.2 poor prognosis 3 (37.5%) 5 (62.5%)   3 (42.9%) 4 (57.1%)  
  1. Achievement of 3 month CHR is presented, stratified by Hasford and Sokal risk profile categories.